{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:39:04Z","timestamp":1781077144514,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1053\/j.seminhematol.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:57:57Z","timestamp":1772841477000},"page":"473-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies"],"prefix":"10.1053","volume":"62","author":[{"given":"Jennifer M.","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Gloude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-911X","authenticated-orcid":false,"given":"Christen L.","family":"Ebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.002_bib0001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41576-022-00527-z","article-title":"Genetics of human telomere biology disorders","volume":"24","author":"Revy","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0002","unstructured":"Savage SA, Niewisch MR. Dyskeratosis congenita and related telomere biology disorders. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R). National Center for Biotechnology Information (NCBI) Bookshelf, Seattle, WA, 1993."},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/hematology.2023000490","article-title":"Clinical manifestations of telomere biology disorders in adults","volume":"2023","author":"Niewisch","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.002_bib0004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1700674","article-title":"Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation","volume":"19","author":"Yabe","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/hematology.2022000394","article-title":"Dyskeratosis congenita and telomere biology disorders","volume":"2022","author":"Savage","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0006","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/asheducation-2011.1.480","article-title":"Dyskeratosis congenita","volume":"2011","author":"Dokal","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0007","unstructured":"Groarke EM, Giri N, Young NS. Medical management of bone marrow failure in telomere biology disorders. In: Telomere biology disorders diagnosis and management guidelines. 2nd ed; 2022. www.teamtelomere.org. https:\/\/teamtelomere.org\/telomere-biology-disorders-diagnosis-and-management-guidelines-downloads\/ Accessed January 5, 2026."},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50111","article-title":"Genotype and associated cancer risk in individuals with telomere biology disorders","volume":"7","author":"Niewisch","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1179\/102453311X12902908411715","article-title":"Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis","volume":"16","author":"Apinantriyo","year":"2011","journal-title":"Hematology"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.002_bib0010","first-page":"299","article-title":"Idiosyncratic drug-induced neutropenia & agranulocytosis","volume":"110","author":"Andres","year":"2017","journal-title":"QJM"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0609.1996.tb01655.x","article-title":"Overview of benzene-induced aplastic anaemia","volume":"60","author":"Smith","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0012","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2016.00364","article-title":"Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output","volume":"7","author":"Pascutti","year":"2016","journal-title":"Front Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.002_bib0013","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/MPH.0000000000001338","article-title":"Hematologic manifestations of nutritional deficiencies: early recognition is essential to prevent serious complications","volume":"41","author":"Yu","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3109\/10428194.2015.1086920","article-title":"Copper deficiency mimicking myelodysplastic syndrome","volume":"57","author":"Rady","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2019003264","article-title":"Cancer spectrum and outcomes in the mendelian short telomere syndromes","volume":"135","author":"Schratz","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.03.002_bib0016","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2024025023","article-title":"Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations","volume":"144","author":"Gutierrez-Rodrigues","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11899-023-00719-2","article-title":"Adaptive and maladaptive clonal hematopoiesis in Telomere Biology disorders","volume":"19","author":"Lasho","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.002_bib0018","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood.2021011075","article-title":"The clinical and functional effects of TERT variants in myelodysplastic syndrome","volume":"138","author":"Reilly","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood.2021013523","article-title":"Disease progression and clinical outcomes in telomere biology disorders","volume":"139","author":"Niewisch","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/17474086.2019.1662720","article-title":"An update on the biology and management of dyskeratosis congenita and related telomere biology disorders","volume":"12","author":"Niewisch","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.002_bib0021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000540109","article-title":"Inherited Telomere Biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment","volume":"51","author":"Rolles","year":"2024","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41525-021-00198-5","article-title":"Telomere biology disorders","volume":"6","author":"Kam","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.002_bib0023","doi-asserted-by":"crossref","first-page":"e181659","DOI":"10.1172\/JCI181659","article-title":"ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders","volume":"135","author":"Sande","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0024","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fimmu.2016.00307","article-title":"Donor-specific anti-HLA antibodies in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Morin-Zorman","year":"2016","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.002_bib0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tmrv.2020.09.010","article-title":"Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness","volume":"34","author":"Saris","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.002_bib0026","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.2023022500","article-title":"How I manage iron overload in the hematopoietic cell transplantation setting","volume":"145","author":"Angelucci","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.002_bib0027","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","article-title":"Iron toxicity and chelation therapy in hematopoietic stem cell transplant","volume":"27","author":"Isidori","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.002_bib0028","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2141.2007.06718.x","article-title":"Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor","volume":"138","author":"Giri","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.002_bib0029","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2008-09-178871","article-title":"Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells","volume":"114","author":"Calado","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.03.002_bib0030","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for Telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.002_bib0031","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/bloodadvances.2018016964","article-title":"Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita","volume":"2","author":"Khincha","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.002_bib0032","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.16997","article-title":"Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita","volume":"193","author":"Kirschner","year":"2021","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.03.002_bib0033","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.3390\/ijms21197196","article-title":"Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita","volume":"21","author":"Vieri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.002_bib0034","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.12748","article-title":"Response to androgen therapy in patients with dyskeratosis congenita","volume":"165","author":"Khincha","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.002_bib0035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.12432","article-title":"Haematological recovery in dyskeratosis congenita patients treated with danazol","volume":"162","author":"Islam","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0036","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/bloodadvances.2025017860","article-title":"Danazol treatment for telomere biology disorders: long-term results of a phase 1\/2 study","volume":"10","author":"Lee","year":"2026","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.002_bib0037","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/bloodadvances.2020001657","article-title":"Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias","volume":"4","author":"Fan","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.002_bib0038","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3324\/haematol.2017.176339","article-title":"Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia","volume":"103","author":"Lengline","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MPH.0000000000002775","article-title":"Severe thrombocytopenia due to bone marrow failure in children with dyskeratosis congenita does not respond to eltrombopag treatment: case series","volume":"46","author":"Pramanik-Jonsson","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.002_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH12-02-0121","article-title":"Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia","volume":"108","author":"Trautmann","year":"2012","journal-title":"Thromb Haemost"},{"issue":"7290","key":"10.1053\/j.seminhematol.2026.03.002_bib0041","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nature08882","article-title":"Zscan4 regulates telomere elongation and genomic stability in ES cells","volume":"464","author":"Zalzman","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.002_bib0042","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/ijms25073898","article-title":"Reprogramming chromosome ends by functional histone acetylation","volume":"25","author":"Meltzer","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.002_bib0043","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.celrep.2017.07.070","article-title":"Zscan4 inhibits maintenance DNA methylation to facilitate telomere elongation in mouse embryonic stem cells","volume":"20","author":"Dan","year":"2017","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0044","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/bs.ctdb.2016.04.004","article-title":"Zygotic genome activation revisited: looking through the expression and function of Zscan4","volume":"120","author":"Ko","year":"2016","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0045","doi-asserted-by":"crossref","first-page":"dsad029","DOI":"10.1093\/dnares\/dsad029","article-title":"ZSCAN4-binding motif-TGCACAC is conserved and enriched in CA\/TG microsatellites in both mouse and human genomes","volume":"31","author":"Akiyama","year":"2024","journal-title":"DNA Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400252","article-title":"Clinical use of ZSCAN4 for telomere elongation in hematopoietic stem cells","volume":"4","author":"Myers","year":"2025","journal-title":"NEJM Evid"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.002_bib0047","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1038\/s41388-020-1333-1","article-title":"ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype","volume":"39","author":"Portney","year":"2020","journal-title":"Oncogene"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.002_bib0048","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41588-023-01339-5","article-title":"Thymidine nucleotide metabolism controls human telomere length","volume":"55","author":"Mannherz","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0049","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1038\/s41467-025-58221-7","article-title":"Metabolic constraint of human telomere length by nucleotide salvage efficiency","volume":"16","author":"Mannherz","year":"2025","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101115","article-title":"Telomere transcription in ageing","volume":"62","author":"Aguado","year":"2020","journal-title":"Ageing Res Rev"},{"key":"10.1053\/j.seminhematol.2026.03.002_bib0051","article-title":"DNA damage response inhibition at dysfunctional telomeres by modulation of telomeric DNA damage response RNAs","volume":"8","author":"Rossiello","year":"2017","journal-title":"Nat Commun"},{"issue":"6963","key":"10.1053\/j.seminhematol.2026.03.002_bib0052","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature02118","article-title":"A DNA damage checkpoint response in telomere-initiated senescence","volume":"426","author":"d'Adda di Fagagna","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.002_bib0053","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1038\/s41467-023-42831-0","article-title":"Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs","volume":"14","author":"Rosso","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.002_bib0054","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41556-022-00842-x","article-title":"Telomere dysfunction in ageing and age-related diseases","volume":"24","author":"Rossiello","year":"2022","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024383","article-title":"Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations","volume":"6","author":"Vulliamy","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.002_bib0056","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2008.07516.x","article-title":"Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients","volume":"144","author":"Kirwan","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.002_bib0057","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.stem.2020.03.016","article-title":"Small-molecule PAPD5 inhibitors restore telomerase activity in patient stem cells","volume":"26","author":"Nagpal","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.03.002_bib0058","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1101\/gad.1476206","article-title":"Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita","volume":"20","author":"Wong","year":"2006","journal-title":"Genes Dev"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.002_bib0059","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41551-025-01429-1","article-title":"Extension of replicative lifespan by synthetic engineered telomerase RNA in patient induced pluripotent stem cells","volume":"9","author":"Nagpal","year":"2025","journal-title":"Nat Biomed Eng"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:54:52Z","timestamp":1781027692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0037196326000144"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}